Pharma BD Deal Intelligence

Gilead Sciences Inc. / LEO Pharma A/S

2025 · Licensing/Option · $1.7B · Complete

Gilead Sciences and LEO Pharma entered a strategic partnership under which Gilead acquired global development, manufacturing and commercialization rights to LEO Pharma's preclinical oral STAT6 program, comprising small molecule oral STAT6 inhibitors and targeted protein degraders, for inflammatory diseases. STAT6 is the transcription factor required for IL-4 and IL-13 signaling, a validated Th2 inflammation axis relevant to atopic dermatitis, asthma and COPD. LEO Pharma receives $250 million upfront and is eligible for up to $1.7 billion in total payments. LEO Pharma retains an option to co-commercialize the oral program in dermatology outside the U.S. and retains exclusive global rights to topical STAT6 formulations in dermatology.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Gilead Sciences Inc. deals  ·  Immunology deals